Aquaretic Effect of Lixivaptan, an Oral, Non-Peptide, Selective V2 Receptor Vasopressin Antagonist, in New York Heart Association Functional Class II and III Chronic Heart Failure Patients

✍ Scribed by William T. Abraham; Alireza A. Shamshirsaz; Kim McFann; Ron M. Oren; Robert W. Schrier

• Book ID: 119265703
• Publisher: Elsevier Science
• Year: 2006
• Tongue: English
• Weight: 175 KB
• Volume: 47
• Category: Article
• ISSN: 1558-3597
• DOI: 10.1016/j.jacc.2005.11.071